- Home
- /
- Mazdutide 10mg
Mazdutide 10mg
Certificate of Analysis
HPLC + Mass Spectrometry included with order
Mazdutide (IBI362, LY3305677) is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics in partnership with Eli Lilly. Unlike Tirzepatide which targets GLP-1 and GIP, Mazdutide targets GLP-1 and glucagon receptors — a different dual agonism profile that emphasises energy expenditure through glucagon-mediated thermogenesis.
Phase 2 and Phase 3 clinical data from trials conducted primarily in China have demonstrated significant efficacy in weight reduction and metabolic parameters. Mazdutide received its first regulatory approval in China in late 2024 and is now under review in additional markets.
This compound represents the glucagon-inclusive approach to metabolic research, complementing the GIP-inclusive approach of Tirzepatide. Kyrolab is one of very few UK sources stocking Mazdutide for research purposes.
COA pending — independent third-party testing in progress. Results will be published to our COA Library upon completion.
Specifications
| Also Known As | IBI362, LY3305677 |
| Developer | Innovent Biologics / Eli Lilly |
| Receptor | Dual GLP-1R + GCGR agonist |
| Regulatory Status | Approved in China (2024) |
| Molecular Weight | ~4200 g/mol |
| Appearance | White lyophilised powder |
| Storage | 2-8°C, protect from light |
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.
| Catalogue Number | KYR-MAZDUTIDE10MG |
| Compound Name | Mazdutide 10mg |